Canopy Growth (CGC) Cash from Operations (2019 - 2025)
Canopy Growth (CGC) reported Cash from Operations of 32664714.37 for Q4 2025, down 69.22% on a YoY basis from 106108586.1 in Q4 2024, and down 337.84% sequentially from 7460342.11 in Q2 2025.
Canopy Growth (CGC) Cash from Operations (2019 - 2025) Analysis & Trends
Canopy Growth (CGC) has 7 years of Cash from Operations data on file, last reported at 32664714.37 in Q4 2025.
- For the quarter ending Q4 2025, Cash from Operations fell 69.22% year-over-year to 32664714.37; the trailing twelve-month figure through Dec 2025 stood at 98905036.64 (up 12.48% YoY), and the FY2026 full-year result was 46527698.38, up 59.72% from the prior year.
- Cash from Operations slipped to 32664714.37 in Q4 2025, from 7460342.11 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 17298539.2 in Q1 2023 to a low of 144448292.26 in Q4 2022.
- A 5-year average of 60043670.14 and a median of 50875761.15 in 2022 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations surged 180.68% in 2023 and plunged 194.63% in 2024, its largest moves.
- Tracing CGC's Cash from Operations over 5 years: stood at 132788593.34 in 2021, then retreated by 8.78% to 144448292.26 in 2022, then jumped by 83.44% to 23923087.58 in 2023, then gained by 19.31% to 19303587.92 in 2024, then sank by 69.22% to 32664714.37 in 2025.
- Business Quant data shows CGC's Cash from Operations at 32664714.37 in Q4 2025, 7460342.11 in Q2 2025, and 19303587.92 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -40.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 401.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 463.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 388.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 145.80 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 13.00 Mn |
| 10 | Canopy Growth | 197.77 Mn | -68.15 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -32.66 Mn |
| Dec 31, 2025 | -32.66 Mn |
| Jun 30, 2025 | -7.46 Mn |
| Jun 30, 2025 | -7.46 Mn |
| Dec 31, 2024 | -19.30 Mn |
| Dec 31, 2024 | -19.30 Mn |
| Sep 30, 2024 | -39.48 Mn |
| Sep 30, 2024 | -39.48 Mn |
| Jun 30, 2024 | -37.86 Mn |
| Jun 30, 2024 | -37.86 Mn |
| Mar 31, 2024 | -16.37 Mn |
| Mar 31, 2024 | -16.37 Mn |
| Dec 31, 2023 | -23.92 Mn |
| Dec 31, 2023 | -23.92 Mn |
| Sep 30, 2023 | -90.33 Mn |
| Sep 30, 2023 | -90.33 Mn |
| Jun 30, 2023 | -79.07 Mn |
| Jun 30, 2023 | -79.07 Mn |
| Mar 31, 2023 | 17.30 Mn |
| Mar 31, 2023 | 17.30 Mn |